Overview
- From September 1, the 5mg list price will rise from £92 to £180 and the 15mg dose will jump from £122 to £330.
- NHS supply and pricing will remain unchanged under a separate agreement negotiated with NHS England.
- Private healthcare providers and online pharmacies will be able to negotiate confidential discounts with Lilly to help patients manage higher costs.
- Clinics warn the price hikes could create affordability barriers for privately paying users and prompt some to switch to alternative GLP-1 treatments such as Wegovy.
- Lilly said the decision reflects recent calls from President Trump and the US administration for global price parity to address international pricing inconsistencies.